Earlier Vasopressin May Help Septic Shock

Earlier vasopressin use in septic shock showed possible benefit, but survival evidence remains uncertain.
*Systematic review/meta-analysis and retrospective cohort; Level 2a (OCEBM).

Citation

Ahn C, Lee GT, Kim JH, et al. Early vasopressin administration in septic shock: A systematic review, meta-analysis, and multicenter retrospective observational study. European Journal of Internal Medicine. 2026;151:106933.

Background

Septic shock often requires norepinephrine to support blood pressure. Vasopressin may reduce the need for higher norepinephrine doses, but the best timing is unclear.

Patients

Adults with septic shock receiving norepinephrine. Registry patients came from 20 Korean hospitals. The review excluded pediatric studies, studies without a comparator or mortality outcome, reviews, case reports, and animal studies.

Intervention

Early vasopressin, defined by each study as earlier time after shock or lower norepinephrine dose.

Control

Later vasopressin or norepinephrine without early vasopressin.

Outcome

Mortality, intensive care unit stay, need for kidney replacement therapy, and abnormal heart rhythms.

Follow-up Period

Primarily 28 days; hospital mortality used when 28-day data were unavailable.

Results

Evidence source Outcome Significant finding
Registry, 2001 vasopressin patients 28-day mortality Starting at norepinephrine ≥0.5 vs <0.25 mcg/kg/min: adjusted OR 2.15 (95% CI 1.59 to 2.92); unadjusted NNH ≈4.
Registry 28-day mortality Starting 6–24 hours vs within 2 hours: adjusted OR 1.59 (95% CI 1.21 to 2.11).
Randomized trials Kidney replacement therapy Early vasopressin: OR 0.46 (95% CI 0.26 to 0.81).
Observational meta-analysis Mortality; intensive care unit stay Mortality OR 0.71 (95% CI 0.60 to 0.84); stay mean difference −1.06 days (95% CI −1.94 to −0.18).

OR = odds ratio; CI = confidence interval; NNH = number needed to harm.

Randomized trials did not show a mortality benefit. Registry analyses used adjusted observational data, not randomized treatment assignment.

Limitations

Most favorable mortality findings came from observational studies, so sicker or differently treated patients may have biased results. “Early” vasopressin was defined differently across studies. Safety outcomes were incompletely reported. The registry was from Korea, which may limit generalizability.

Funding

Korean government health research grants; no reported funder role.

Clinical Application

Consider vasopressin before very high norepinephrine doses, but do not treat this as definitive survival evidence pending better randomized trials.